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Peptide-siRNA nanotherapeutics in arthritis
Christine T.N. Pham, Hua Pan and Samuel A. Wickline
RNA interference (RNAi) is a process that involves 
the delivery of small single stranded RNA molecules 
into mammalian cells, resulting in the sequence-specific 
cleavage of complementary mRNA and the silencing of 
specific gene expression. These small RNA molecules 
called small interfering RNAs (siRNAs) are the focus 
of intense research due to their potential therapeutic 
uses in various disease processes ranging from cancer 
to autoimmune and inflammatory conditions. However, 
critical barriers to the delivery of siRNAs in vivo remain. 
“Off-target” effects due to the suppression of closely 
related or unrelated genes might lead to unintended 
and potentially harmful host responses. Additionally, 
unprotected siRNAs are highly unstable once introduced 
into the circulation, with half-life of less than ten minutes, 
as they are quickly degraded by endogenous nucleases. 
Effective delivery of siRNAs to the desired cells/
tissues requires specialized delivery strategies as naked 
siRNAs penetrate cell membrane poorly due to their 
negative charge. Different carrier systems have been 
developed to enhance siRNA delivery, including cationic 
lipid- and polymer-based nanoparticle formulations. 
However, potential toxicities have hindered the clinical 
translation of these platforms. Several cell-penetrating 
peptides (CPP) have also been used to enhance 
intracellular uptake of siRNAs. Excessive endosomal 
entrapment, however, remains the primary barrier to many 
CPP-mediated delivery systems. 
Melittin is a well-studied peptide with cell lytic 
potential through its lipid membrane binding and pore 
forming property. Our studies of the peptide structure-
function relationships and peptide-lipid interactions led to 
modifications that yielded an amphipathic cationic peptide 
called “p5” that serves as a “peptide linker” capable of 
rapidly functionalizing lipid membranes with cargo such 
as targeting ligands, drugs, and imaging contrast agents 
but is now substantially less lytic (a 5,700% decrease) 
compared to native melittin [1-3]. Further modifications 
of p5, based on studies of nucleotide-peptide interactions, 
were shown to enable a number of other useful attributes 
such as protected siRNA transport in circulation and rapid 
delivery to target tissues through passive permeation in 
addition to endosomal escape after pinocytotic uptake 
and concomitant rapid release of siRNA that depends 
on endosomal acidification and peptide protonation [4, 
5]. Unlike the present class of lipid-based carriers, our 
peptide carrier for siRNA delivery is not sequestered 
in the reticuloendothelial system but is cleared renally. 
Avoidance of liver/spleen sequestration and renal 
clearance of active peptide-siRNA nanoparticles also serve 
to promote more focused tissue interactions, particularly 
under conditions of inflammation and enhanced vascular 
permeability as in cancers [5]. Finally, the approach is 
agnostic as to the exact oligonucleotide sequence, and 
the entire complex can be formed within as little as 
ten minutes by a simple mixing procedure that allows 
noncovalent, self-assembly of cationic and anionic 
moieties into a ~55 nm nanocomplex ready for direct 
injection or else fully stabilized for later use by mixing in 
albumin. The resulting material is stable in both blood and 
plasma from hours to days as previously reported [4, 5].
Rheumatoid arthritis (RA) is a chronic inflammatory 
condition affecting approximately 1% of the population 
worldwide. Despite recent advances in therapeutics, 
30-40% of RA patients fail to respond to these new 
medications or are forced to cease treatment due to 
adverse effects. In our recent work [6], we examined the 
ability of our peptide-siRNA nanoplatform to silence p65, 
a major effector of the NF-κB canonical signaling pathway 
that controls the expression of various inflammatory 
mediators, including TNF-α, IL-1β, and IL-6. Although 
NF-κB represents an attractive therapeutic target for 
inflammatory arthritis, its generalized suppression can 
result in serious host toxicity, as NF-κB is critically 
involved in innate and adaptive immune responses. Using 
the anti-collagen antibody induced arthritis (CAIA) 
model we showed that anti-p65 siRNA nanocomplexes 
homed to the inflamed paws through leaky vasculature, 
localized to synovial macrophages and suppressed 
ongoing arthritis in 6-8 week-old male DBA1/J mice 
while equivalent doses of naked anti-p65 siRNA did not 
alter the disease progression. Moreover, joint-associated 
levels of multiple inflammatory cytokines (TNF-α, IL-1β, 
IL-6, and MCP-1) were all profoundly suppressed in mice 
treated with anti-p65 siRNA nanocomplexes. We showed 
that p65 mRNA and protein expression were specifically 
downregulated only in the paws of these animals while 
levels of related NF-κB family members (p100/52, 
p105/50, RelB) were preserved. In addition, p65 and 
related NF-κB protein levels in off-target organs such as 
liver, spleen, brain, and kidneys were unperturbed. More 
importantly, our initial studies suggest that serial systemic 
injections of the peptide-siRNA nanocomplexes did not 
elicit complement activation or specific humoral response 
[6]. In summary, modifications of the native melittin led 
to the formulation of a self-assembling nanoplatform that 
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may realistically offer safe, effective and highly specific 
in vivo delivery of siRNAs for the treatment of RA and 
potentially many other inflammatory conditions that 
require chronic and repeated injections.
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